Tagrisso has been recommended for use as an adjuvant treatment following complete resection in adults with stage 1B to 3A non-small cell lung cancer (NSCLC) whose tumours express epidermal growth factor (EGFR) exon 19 deletions or exon 21 substitution mutations.
Meanwhile, Imfinzi (durvalumab) has been recommended for use in combination with etoposide plus either carboplatin or cisplatin to treat adults with untreated extensive-stage small cell lung cancer (SCLC).
Approximately 49,200 people are diagnosed with lung cancer in the UK every year. NSCLC is the most common form of the disease, accounting for around 85% of cases, while SCLC represents approximately 15% of all diagnoses…
